Jon Salmanton-García

ORCID, self-asserted

ORCID 0000-0002-6766-8297

Publications

Citations

1,010

h-index

Computed over the works the graph holds, so it is a floor rather than a career figure.

i10-index

Publications

31 works in the graph, newest first.

Invisible fungal disease, visible consequences: diagnostic capacity and antimicrobial resistance in Africa
2026The Lancet Regional Health - AfricaJournalOpen accessSenior authorCorresponding0 citations10.1016/j.lanafr.2026.100127
Closing the gap on antifungal resistance
2026Nature MedicineJournal2 citations10.1038/s41591-026-04334-5
Profiling medical mycologists: Results from a global survey of the ESCMID Fungal Infection Study Group (EFISG)
2026Medical MycologyJournalOpen accessFirst authorCorresponding1 citations10.1093/mmy/myag037
Clinical Characteristics, Management and Outcomes of Nonintensive Care Unit Candidemia: Subanalysis of the ECMM Candida III Multinational European Observational Cohort Study
2026Open Forum Infectious DiseasesJournalOpen access0 citations10.1093/ofid/ofag133
Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Human Metapneumovirus in Hematological Malignancy, Insights From EPICOVIDEHA/EPIRESEHA Registry
2026Open Forum Infectious DiseasesJournalOpen accessFirst authorCorresponding1 citations10.1093/ofid/ofag099
Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM
2025The Lancet Infectious DiseasesJournalOpen access372 citations10.1016/s1473-3099(24)00749-7
ESCMID‐EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance
2025MycosesJournalOpen accessSenior authorCorresponding5 citations10.1111/myc.70092
Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS‐COV‐2—A Report From the EPICOVIDEHA/EPIRESEHA Registry
2025American Journal of HematologyJournalOpen accessFirst authorCorresponding2 citations10.1002/ajh.70166
P-2271. Unraveling the Past: Analyzing the Effects of COVID-19 on Hematological Malignancy Patients - Observations from 2020 to 2022
2025Open Forum Infectious DiseasesJournalOpen access0 citations10.1093/ofid/ofae631.2424
Performance of recombinase polymerase amplification-based assay (RPA) for rapid detection of fungal pathogens in clinical samples of patients in Abidjan, Côte d’Ivoire
2025Journal de Mycologie MédicaleJournal1 citations10.1016/j.mycmed.2025.101579
Elevating fungal care: bridging Brazil’s healthcare practices to global standards
2025Microbiology SpectrumJournalOpen accessFirst author10 citations10.1128/spectrum.02112-24
Global guideline for the diagnosis and management of cryptococcosis: an initiative of the ECMM and ISHAM in cooperation with the ASM
2024The Lancet Infectious DiseasesJournalOpen access324 citations10.1016/s1473-3099(23)00731-4
Antifungal pipeline: New tools for the treatment of mycoses
2024Revista Iberoamericana de MicologíaJournalOpen access20 citations10.1016/j.riam.2024.11.001
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry
2024HaematologicaJournalOpen access7 citations10.3324/haematol.2023.284678
Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
2024EClinicalMedicineJournalOpen accessFirst authorCorresponding34 citations10.1016/j.eclinm.2024.102553
Perspectives of European Patient Advocacy Groups on Volunteer Registries and Vaccine Trials: VACCELERATE Survey Study
2024JMIR Public Health and SurveillanceJournalOpen access4 citations10.2196/47241
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA ‐ EPIFLUEHA Report
2024American Journal of HematologyJournalOpen accessFirst authorCorresponding15 citations10.1002/ajh.27565
Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B)
2024International Journal of Infectious DiseasesJournalOpen access1 citations10.1016/j.ijid.2024.107161
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
2024InfectionJournalOpen accessCorresponding10 citations10.1007/s15010-023-02169-7
Fungal diseases in Africa: Closing the gaps in diagnosis and treatment through implementation research and advocacy
2023Journal de Mycologie MédicaleJournalOpen access35 citations10.1016/j.mycmed.2023.101438
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
2023EClinicalMedicineJournalOpen accessFirst author34 citations10.1016/j.eclinm.2023.101939
Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
2023International Journal of Infectious DiseasesJournalOpen accessCorresponding16 citations10.1016/j.ijid.2023.10.013
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
2023Hematological OncologyJournalOpen accessCorresponding16 citations10.1002/hon.3240
The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey
2023Leukemia & lymphoma/Leukemia and lymphomaJournalOpen accessCorresponding10 citations10.1080/10428194.2023.2280886
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry
2023Therapeutic Advances in HematologyJournalOpen accessCorresponding9 citations10.1177/20406207231154706
Unveiling the Hidden Burden: From EPICOVIDEHA to EPIFLUEHA, Exploring the Epidemiology of Respiratory Viral Infections in Hematological Patients
2023HemaSphereJournalOpen accessFirst authorCorresponding6 citations10.1097/hs9.0000000000000970
S292: NIRMATRELVIR/RITONAVIR IN COVID-19 PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: A REPORT FROMTHE EPICOVIDEHA REGISTRY
2023HemaSphereJournalOpen accessFirst author0 citations10.1097/01.hs9.0000968080.61947.d1
COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)
2022HaematologicaJournalOpen access52 citations10.3324/haematol.2022.280847
COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey
2022Blood AdvancesJournalOpen access12 citations10.1182/bloodadvances.2022007357
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey
2022CancersJournalOpen accessCorresponding11 citations10.3390/cancers14225530
S281: PRIOR EXPOSURE TO IMMUNOSUPPRESSIVE AGENTS AND COMORBIDITIES ARE ASSOCIATED WITH WORSE OUTCOMES OF SARS-COV2 INFECTION IN PH-NEG CHRONIC MYELOPROLIFERATIVE NEOPLASMS: RESULTS OF EPICOVIDEHA SURVEY
2022HemaSphereJournalOpen access0 citations10.1097/01.hs9.0000844016.51035.29